Lack of endocrine systemic side effects after topical application of spironolactone in man

  title={Lack of endocrine systemic side effects after topical application of spironolactone in man},
  author={F Rey and C. Valterio and Luigi Locatelli and Albert Adrien Ramelet and J. P. Felber},
  journal={Journal of Endocrinological Investigation},
In six healthy male volunteers, the percutaneous absorption of spironolactone was compared with placebo in a double-blind crossover study. The subjects were randomly given either a cream containing 5% spironolactone or placebo to be applied in a randomized sequential way to a well defined skin area equivalent to 55% of body area. During the 72 h following the application of the ointment, blood levels of canrenone, the major metabolite of spironolactone, have been determined. In order to… Expand
Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial
The 5% spironolactone topical gel resulted in a decrease in the TLC in acne vulgaris, while it had no significant efficacy in the ASI. Expand
Facial contact dermatitis due to spironolactone in an anti‐acne cream
Systemic spironolactone has been successfully prescribed in patients affected by androgen-related disorders such as acne vulgaris, hirsutism and androgenic alopecia and is proposed as a new therapeutic approach for both men and women. Expand
CV 205–502 treatment of macroprolactinomas
CV 205–502, given once daily, appears to be a safe and effective alternative to other dopamine agonists in the treatment of macroprolactinoma, by reducing hyper Prolactinemia and tumor size. Expand
Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: A pilot study
The topical 5% spironolactone cream seems to be an effective and safe treatment of acne vulgaris in both male and female patients. Expand
Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series
Background: Although 50% to 90% of patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash, options for rash prevention or palliation remain limited. This issue isExpand
When Testosterone Needs to be Contrasted: A Preliminary Study of Scar Prevention in Transmen Top Surgery with an Innovative Galenic Preparation
TSSgo scar innovative treatment showed long-term efficacy in comparison with silicon gel in terms of improved scar tissue texture, pigmentation, pliability and height and appears to be promising as the new treatment of reference for scar management after top surgery in transmen. Expand


The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.
It is suggested that the antiandrogenic effects of S are primarily related to its peripheral effect, as there is no good clinical marker for this effect as levels of 3 alpha-diol and 3alpha-Diol-G increase. Expand
Effect of spironolactone on sex hormones in man.
Findings are consistent with a previously-reported spironolactone-induced destruction of the microsomal enzyme cytochrome P-450, an enzyme necessary for 17-hydroxylase and desmolase activity and do not explain the decrease of libido, the impotence, and the gynecomastia frequently associated with spironOLactone therapy in males. Expand
Although spironolactone was not consistently successful, it may represent effective therapy for a sub group of patients with hirsutism and there was subjective benefit in hair growth and greasiness and a significant reduction in the semi‐objective Ferriman‐Gallwey index. Expand
Antiandrogenic effect of spirolactones: mechanism of action.
It seems likely that spirolactones, besides their action on testosterone biosynthesis, exert their antiandrogenic activity via a peripheral androgen antagonism. Expand
Gynecomastia and semen abnormalities induced by spironolactone in normal men.
The clinical and hormonal effects of spironolactone on the pituitary-testicular axis were evaluated in healthy, young men and no change occurred in the mean serum concentrations of FSH, LH, testosterone or estradiol. Expand
Antiandrogenic effects of topically applied spironolactone on the hamster flank organ.
Topically administered spironolactone appears to have only local antiandrogenic effects, as indicated by the lack of changes in the untreated contralateral flank organs and in the weights of seminal vesicles. Expand
Lack of effect of topical spironolactone on sebum excretion
Patients with moderately severe facial acne were randomly allocated to three treatment groups and the anti-androgenic effect was tested by measuring SER on the forehead by the method of Strauss and Pochi, as modified by Cunliffe and Shuster (1969). Expand
Treatment of hirsutism with spironolactone.
Spironolactone is a highly effective and safe agent for the treatment of hirsutism through its inhibitory action on both ovarian androgen secretion and peripheral androgen action. Expand
Oral spironolactone improves acne vulgaris and reduces sebum excretion
The clinical response was dose‐dependent, with maximum subjective and objective benefit when spironolactone doses of 150–200 mg were used, but there was no correlation between sebum response and androgen status. Expand
The effect of spironolactone on genital skin 5α-reductase activity
In conclusion, S has a direct inhibitory effect on 5 α-RA and the beneficial effect of S treatment in HW may be related, in part, to this inhibition of 5α-RA. Expand